Dan G. Duda, DMD, Ph.D., of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at ...

Dose-finding clinical trial in China designed to evaluate safetyand preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in ...

MAIA Biotechnology Granted FDA Rare Pediatric Disease Designation for THIO as a Treatment for Pediatric High-Grade Gliomas ...

Research has revealed that in the case of metabolic dysfunction-associated fatty liver disease (MAFLD), the risk of ...

Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment ...

(Michelle Mullins/for the Daily Southtown) Addy was diagnosed with metastatic hepatocellular carcinoma in July 2021. That ...

The TIME is a dynamic network composed of cancer cells, immune cells, and stromal components. During the early stages of ...

Hepatocellular carcinoma (HCC) stands as the dominant form of liver cancer, ranking as the fourth leading cause of cancer-related deaths globally.

Hepatocellular carcinoma (HCC) is a significant global health issue, ranking as the sixth most prevalent malignancy and the ...

Hepatitis delta virus testing in those with chronic hepatitis B is low, and improvements are needed to reduce long-term, ...

Importantly, hepatocellular carcinoma (HCC), the most common form of liver cancer, is now the fifth leading cause of cancer-related deaths in the United States and is projected to rise to the third by ...